Cite
Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.
MLA
Chhatwal, Jagpreet, et al. “Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States.” Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 16, no. 6, Sept. 2013, pp. 973–86. EBSCOhost, https://doi.org/10.1016/j.jval.2013.07.006.
APA
Chhatwal, J., Ferrante, S. A., Brass, C., El Khoury, A. C., Burroughs, M., Bacon, B., Esteban-Mur, R., & Elbasha, E. H. (2013). Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 16(6), 973–986. https://doi.org/10.1016/j.jval.2013.07.006
Chicago
Chhatwal, Jagpreet, Shannon A Ferrante, Cliff Brass, Antoine C El Khoury, Margaret Burroughs, Bruce Bacon, Rafael Esteban-Mur, and Elamin H Elbasha. 2013. “Cost-Effectiveness of Boceprevir in Patients Previously Treated for Chronic Hepatitis C Genotype 1 Infection in the United States.” Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research 16 (6): 973–86. doi:10.1016/j.jval.2013.07.006.